GlassScriptPhysician profile
Christopher A Yandell
NPI 1134732738
$9,161.10
in general payments reported to CMS, 2019-2025
59 companies · $2,307 in 2025
The $2,307 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $746 · 2022: $1,822 · 2023: $2,020 · 2024: $2,267 · 2025: $2,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,424 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,424.13 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $794.50 | 2021-2025 | Rybrevant, Akeega, Erleada |
| Novartis Pharmaceuticals Corporation | $746.06 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $533.26 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Celgene Corporation | $523.58 | 2021-2025 | Reblozyl, Pomalyst, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $466.91 | 2021-2025 | Tagrisso, Enhertu, Imfinzi |
| Seagen INC. | $385.80 | 2021-2023 | Adcetris |
| Regeneron Healthcare Solutions, INC. | $355.95 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $342.11 | 2021-2025 | Tecentriq, Phesgo, Alecensa |
| Astellas Pharma US INC | $317.84 | 2021-2025 | Padcev, Vyloy, Cresemba |
| Lilly USA, LLC | $295.08 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $289.80 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Amgen INC. | $284.00 | 2021-2023 | Lumakras, Kyprolis, Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $277.93 | 2022-2025 | Ninlaro |
| Incyte Corporation | $246.46 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Merck Sharp & Dohme LLC | $209.03 | 2022-2025 | Keytruda, Welireg, Lynparza |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $198.12 | 2021-2025 | |
| Eisai INC. | $172.81 | 2021-2025 | |
| Abbvie INC. | $167.73 | 2022-2025 | |
| Gilead Sciences, INC. | $165.73 | 2021-2025 | Trodelvy |
| Pfizer INC. | $162.69 | 2022-2024 | |
| Glaxosmithkline, LLC. | $156.08 | 2021-2024 | Jemperli |
| Deciphera Pharmaceuticals INC. | $149.86 | 2022-2025 | Qinlock, Romvimza |
| Bayer Healthcare Pharmaceuticals INC. | $129.63 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $120.71 | 2022-2025 | |
| Beone Medicines USA, INC. | $118.39 | 2025 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $113.93 | 2022-2024 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $101.34 | 2022-2025 | Rezlidhia, Gavreto, Tavalisse |
| Taiho Oncology, INC. | $99.31 | 2022-2025 | |
| Beigene USA, INC. | $98.53 | 2023-2024 | Brukinsa, Tevimbra |
| Ipsen Biopharmaceuticals, INC | $88.15 | 2021-2024 | Onivyde |
| Kyowa Kirin, INC. | $87.46 | 2022-2024 | Poteligeo |
| Pharmacyclics LLC, An Abbvie Company | $78.11 | 2021-2023 | Imbruvica |
| Pharmacosmos Therapeutics INC. | $64.68 | 2025 | Monoferric |
| Array Biopharma INC | $63.95 | 2024-2025 | Mektovi, Lorbrena, Braftovi |
| Jazz Pharmaceuticals INC. | $54.74 | 2021-2024 | |
| Mirati Therapeutics, INC. | $54.41 | 2023-2024 | Krazati |
| Pharmaessentia USA Corporation | $46.38 | 2022-2025 | Besremi |
| Genmab U.S., INC. | $45.94 | 2024 | Epkinly |
| Legend Biotech USA INC. | $44.38 | 2024-2025 | Carvykti |
| Exelixis INC. | $43.89 | 2021-2024 | Cabometyx |
| Iovance Biotherapeutics, INC. | $43.24 | 2025 | Amtagvi |
| Sobi, INC | $40.89 | 2022-2024 | |
| Boston Scientific Corporation | $40.13 | 2024 | Rezum Generator |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.42 | 2021 | |
| Tempus Ai, INC | $29.43 | 2024 | Xt Cdx |
| Agios Pharmaceuticals, INC. | $28.76 | 2024 | |
| Servier Pharmaceuticals LLC | $26.19 | 2025 | |
| Karyopharm Therapeutics INC. | $25.00 | 2025 | Xpovio |
| Tersera Therapeutics LLC | $24.58 | 2024 | Xermelo |
| Immunocore Limited | $22.09 | 2023 | Kimmtrak |
| Puma Biotechnology, INC. | $19.79 | 2022 | |
| Emd Serono, INC. | $19.11 | 2025 | |
| Tg Therapeutics, INC. | $18.05 | 2021 | |
| Adaptive Biotechnologies Corporation | $17.99 | 2024 | Clonoseq |
| Morphosys, US INC. | $17.50 | 2023 | Monjuvi |
| Geron Corporation | $16.50 | 2025 | Rytelo |
| Syndax Pharmaceuticals, INC. | $16.36 | 2025 | |
| Aadi Bioscience, INC. | $14.02 | 2023 | Fyarro |
| Epizyme, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Yandell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.